EWTX

Edgewise Therapeutics, Inc.
CAPPED RATING

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics, Inc. (EWTX) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B+
Factor Score 3.7 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 5.6
EV / EBITDA -15.5
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 6.8%
Price Return 12M 171.2%
Catalyst Signal 0.00
Market Cap $5.1B
TTM Revenue N/A
Price / Sales N/A
ROE 92.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B+ (3.7) D- (0.9) B- (2.9) B- (3.1) C+ (2.6) C+ (2.7)
2026-11-04 C+ (2.5) D- (0.9) C+ (2.7) B- (2.9) C+ (2.7) C (2.3)
2026-10-28 C+ (2.5) F (0.2) C+ (2.7) B- (3.1) C+ (2.7) C (2.2)
2026-10-21 C+ (2.5) F (0.2) C+ (2.7) B (3.2) C+ (2.6) C (2.2)
2026-10-14 C+ (2.5) F (0.2) C+ (2.7) B- (3.1) C+ (2.6) C (2.2)
Page 1 of 4